Competitive Dashboard
The top players operating in the clinical reference laboratories market include KingMed Diagnostics, Laboratory Corporation of America, Sonic HealthCare Limited, Aurora Diagnostics, Bioreference Laboratories, Synlab International GmbH, Clinical Reference Laboratory, Unilabs, Quest Diagnostics, ARUP Laboratories, and others.
Industry Updates
A worldwide leader in innovative laboratory R&D and national reference laboratory, ARUP Laboratories, along with Techcyte, have recently developed the world’s first AI-augmented parasite and ova detection equipment. This will enable reduced cost, faster turnaround times, improved patient care, and employee satisfaction.
Market Overview
The global clinical reference laboratories market, as per a report by Market Research Future (MRFR) is touted to register a CAGR of 5.8 % during the forecast period (2016-2027).
Request a Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1190
Clinical reference laboratories are extensively used to support analysis and diagnosis in patient care as in medical research. Laboratory services are essential for treatment, disease diagnosis, disease surveillance programs, monitoring response to treatment, and clinical research. Generation of quality results involves stepwise procedure through implementation, planning, and thorough checking of results. Laboratories carry out extramural and intramural research through institutions involved in daily patient care.
The clinical reference laboratories market has been evaluated as a progressively evolving market and is likely to retain its position in the foreseeable future. The adoption of value-based services has gained traction as hospitals have started outsourcing radiology and pathology diagnostic services. With hospital budgets becoming constrained due to declining medical reimbursements, hospitals are outsourcing their pathology and diagnostic services. The rising value-based outsourcing from hospitals has encouraged the market for independent reference laboratory services.
Increased use of robotics technology in reference laboratories to increase productivity, reduce lab process cycle times, and elevate data quality are some of the major factors likely to contribute to the market growth across the globe. Moreover, the application of laboratory automation technology will help to enhance the effectiveness and efficiency of testing and diagnostic process. Laboratories will also be able to perform critical activities like combination chemistry, screening, large-scale biorepositories, and automated clinical and analytical testing. Such factors are likely to influence the market across the globe. The soaring focus on early detection and prevention of diseases, revolution of personalized medicines, and innovation of genetic and molecular technologies are some of the factors likely to dictate the growth trajectory of the market. Increased number of FDA approvals for diagnostic procedures will further lead to vendors emphasizing on the launch of cost-effective, new, and time-saving diagnostic procedures in order to increase the market shares.
Regional Frontiers
Geographically, the clinical reference laboratories market spans across Asia Pacific, Europe, North America, and the Middle East & Africa.
Considering the global scenario, North America is predicted to lead the global market, with economies like Canada and the U.S. playing a major role in the industry. Europe acquires the second spot in the global market and is likely to retain its position in the coming years.
The Asia Pacific, on the other hand, is likely to expand at the fastest rate. The presence of a large patient population base, increasing initiatives by the government to increase awareness regarding regular check-ups and preventive care, improving healthcare infrastructure, and penetration of advanced clinical laboratory technologies are likely to contribute to the market growth in the region.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/clinical-reference-laboratories-market-1190
Clinical Reference Laboratories Market: Segmental Analysis
The clinical reference laboratories market has been segmented on the basis of service providers and applications.
By service providers, the clinical reference laboratories market is segmented into hospital-based, stand-alone, and clinical based.
By application, the clinical reference laboratories market is segmented into clinical trials, laboratory medicine, and others.
Browse More Healthcare Related Research Reports:
Asthma and COPD Drugs Market Size, Trends | Share Analysis, 2025
Impact of COVID-19 Outbreak on Healthcare Market
Cardiac Mapping Market Trends, Growth | Size Analysis, 2025
NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
Covid19 Impact on Non-Alcoholic Steatohepatitis (NASH) Biomarkers Global Market 2020- Growth factors, Demand, Current Scenario, Size, Share Investment, Business Opportunities and Challenges Non-Alcoholic Steatohepatitis (NASH) Biomarkers Global Market OverviewNASH biomarkers are helpful in the identification of liver damage and the severity of the disease.
This disease leads to risks as dangerous as liver failure.
Non-alcoholic steatohepatitis biomarkers global market is projected to grow at nearly 21% rate annually.
Now it has become necessary for companies to keep their eyes and ears open to reach for any advancement, as any cure found can help them in gaining hefty profits and the demands would be high at initial stages.Apart from all these factors, there are some constraints faced by the industry.
Factors like the rising occurrence of related diseases, governmental initiatives for awareness & development and already established developed healthcare with increasing demands are responsible for such massive growth in this market.
Europe is in second place due to the same features mentioned above.Asia Pacific market will show moderate growth due to rising population, developments & efforts made for better health infrastructure, the increase in the number of patients and large population.
Preimplantation Genetic Diagnosis Market:WiseGuyReports.com adds “Global Preimplantation Genetic Diagnosis Market Research Report 2020 Analysis and Forecast 2026” reports to its database.Executive SummaryGlobal Preimplantation Genetic Diagnosis Market is valued approximately USD 407.04 Million in 2019 and is anticipated to grow with a healthy growth rate of more than 10% over the forecast period 2019-2026.
The testing is done when one or both genetic parents has a known genetic abnormality.
Therefore, such test is performed on embryo to identify or determine any genetic abnormality or disorders.
Due to such favorable offering of preimplantation genetic diagnosis people across the globe are adopting such tests, hence increasing awareness among people regarding preimplantation genetic diagnosis coupled with rising incidence of newborn baby with genetic disorders across the globe drives the growth of market over the forecast years.
In Addition, rising number of fertility clinics worldwide are the factors driving the growth of market over the upcoming years.
However, high Procedural cost associated with preimplantation genetic testing is the factor hampers the growth of market.Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/5278138-global-preimplantation-genetic-diagnosis-market-size-study-byThe regional analysis of global Preimplantation Genetic Diagnosis market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World.
Market HighlightsFactors such as the increasing prevalence of chronic diseases and rising therapeutics demand are estimated to drive the market growth during the forecast period.
Request Sample Copy:https://www.marketresearchfuture.com/sample_request/5989SegmentationThe global esoteric testing market is segmented on the basis of test type, technology, end-user, and region.
Considering test type, the market is segmented into infectious diseases testing, endocrinology testing, oncology testing, genetic testing, toxicology testing, immunology testing, neurology testing, and others.
By technology, the market is segmented into chemiluminescence immunoassay, enzyme-linked immunosorbent assay, mass spectrometry, real-time PCR, flow cytometry, radioimmunoassay, and others.
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa.
Regional AnalysisThe Americas dominates the global esoteric testing market owing to the increasing prevalence of chronic diseases and presence of a well-developed healthcare sector within the region.
According to the new market research report “Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Genetic Testing), Technology (MS, CLIA, ELISA, PCR), End User (Independent & Reference Laboratories, Hospital Laboratories) – Global Forecast to 2026″, published by MarketsandMarkets™, the global market is projected to reach USD 36.3 billion by 2026 from USD 21.0 billion in 2021, at a CAGR of 11.6% during the forecast period.Browse and in-depth TOC on “Esoteric Testing Market”134 – Tables47 – Figures244 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76794708The rising incidence of chronic and infectious diseases, increasing use of esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer, and advancements in the personalized medicine are the major factors driving the growth of the market.In 2020, infectious diseases accounted for the largest share of the Esoteric Testing Market.
The genetic testing segment is expected to grow at the highest CAGR during the forecast period.Based on the type, the market is segmented into infectious disease testing, endocrinology testing, oncology testing, genetic testing, toxicology testing, immunology testing, neurology testing, and other testing.
In 2020, the infectious disease testing segment accounted the largest share of the Esoteric Testing Market.
The largest share of the segment is attributed to the increasing incidence of infectious diseases, technological innovations in molecular diagnostics, and improving healthcare infrastructure in developing nations.
The genetic testing segment is expected to register the highest CAGR during the forecast period.
The fastest growth of the genetic testing segment is attributed to the advancements in the sequencing technologies such as NGS and increasing awareness.CLIA segment account for the largest share of the market in 2020.Based on technology, Esoteric Testing Market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), mass spectrometry, real-time PCR, flow cytometry, DNA sequencing, and other technologies.
The global rare disease genetic testing market size is expected to reach USD 1.8 Billion by 2027 according to a new study by Polaris Market Research.
The report “Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Neurological Disorders, Immunological Disorders, Hematology Ailments, Endocrine & Metabolism Disorders, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disorders, Others); By Technology; By Specialty; By End-Use; By Regions; Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The growing need for on-time diagnosis of uncommon disorders, rising prevalence of rare disorders, innovations in genomic testing, and the focused approach of the market player’s in cost-effective treatments are the key factors responsible for market growth.
Moreover, government-sponsored schemes are also expected to positively impact the market.
In February 2020, the government of India announced financial assistance of INR 15 lacs to the patients suffering from uncommon ailments under the Rashtriya Arogaya Nidhi scheme for a one-time treatment.
The global rare disease genetic testing industry is fragmented based on disease type, technology, specialty, end-use, and region.
The global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study by Polaris Market Research.
The report “Cervical Dysplasia Market Share, Size, Trends, Industry Analysis Report, By Type (Diagnostic Tests, {HPV Test, Pap Smear Test, Biopsy Test}, Diagnostic Devices, Colposcope); By End-Use (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers), By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The rising prevalence of cervical cancer and awareness regarding its early diagnosis is the key cervical dysplasia industry impacting factors.
Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/cervical-dysplasia-market/request-for-sample Moreover, Cervical Awareness Month was introduced by the U.S. Congress, in 2019, to declare the month of January dedicated to the patients suffering from cervical cancer in the market.
For instance, in January 2020, both Japan pharmaceutical giants ASKA Pharmaceutical and KinoPharma entered into a collaborative agreement for the development and commercialization of drug candidates for cervical dysplasia in the market, which is under preclinical phase under KinoPharma.
Under the agreement, ASKA would obtain exclusive rights to sell the drug in the Japanese market and will help later in co-developing potential drug candidates and KinoPharma in return will receive upfront payments for the exclusive licensing.
